Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 25, 2018 -- Portola Pharmaceuticals, Inc.^® (Nasdaq:PTLA) today announced that new interim results from the Company’s ongoing Phase 2a study of cerdulatinib in patients with Non-Hodgkin Lymphoma (NHL), including B-cell NHL and relapsed/refractory peripheral T-cell lymphoma (PTCL), will be presented during a Poster Discussion Session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, in Chicago.   

Cerdulatinib is an investigational oral, dual SYK/JAK kinase inhibitor that uniquely inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies. It is being developed for the treatment of resistant or relapsed hematologic cancer.

Poster Presentation Details:

• Presentation Title: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study in Patients with Relapsed/Refractory B- and T-Cell Non-Hodgkin Lymphoma (NHL)
  
  
• Presenter: Paul A. Hamlin, M.D., Memorial Sloan Kettering Cancer Center
  
  
• Abstract Number: 7511 
  
  
• Poster Board: 148
  
  
• Session Title: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
  
  
• Date and Time: Monday, June 4, 2018 from 1:15 p.m. – 2:30 p.m. CT
  
  
• Location: E450, McCormick Place

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa^® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.